-
Something wrong with this record ?
Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study
C. Charles-Schoeman, J. Schessl, Z. Bata-Csörgő, MM. Dimachkie, Z. Griger, S. Moiseev, CV. Oddis, E. Schiopu, J. Vencovský, E. Clodi, T. Levine, R. Aggarwal
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
Grant support
Octapharma Pharmazeutika Produktionsges.m.b.H.
Portland Medical Communications Ltd
Octapharma
AstraZeneca
- MeSH
- Autoantibodies blood immunology MeSH
- Dermatomyositis * drug therapy immunology MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Immunologic Factors * therapeutic use MeSH
- Immunoglobulins, Intravenous * therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Aged MeSH
- Severity of Illness Index MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM. METHODS: ProDERM was a prospective, randomized, placebo-controlled study of DM patients. For weeks 0-16, patients received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies. RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications. Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-γ antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-γ) and efficacy outcome. CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-γ responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02728752.
Department of Dermatology and Allergology University of Szeged Szeged Hungary
Department of Neurology University of Kansas Medical Center Kansas City KS USA
Division of Clinical Immunology Faculty of Medicine University of Debrecen Debrecen Hungary
Division of Rheumatology Department of Medicine University of California Los Angeles CA USA
Division of Rheumatology Medical College of Georgia at Augusta University Augusta GA USA
Global Medical and Scientific Affairs Octapharma Pharmazeutika Produktionsges m b H Vienna Austria
Phoenix Neurological Associates Ltd Phoenix AZ USA
Tareev Clinic of Internal Diseases Sechenov 1st Moscow State Medical University Moscow Russia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015561
- 003
- CZ-PrNML
- 005
- 20250731091056.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/keaf070 $2 doi
- 035 __
- $a (PubMed)39918968
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Charles-Schoeman, Christina $u Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, USA
- 245 10
- $a Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study / $c C. Charles-Schoeman, J. Schessl, Z. Bata-Csörgő, MM. Dimachkie, Z. Griger, S. Moiseev, CV. Oddis, E. Schiopu, J. Vencovský, E. Clodi, T. Levine, R. Aggarwal
- 520 9_
- $a OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM. METHODS: ProDERM was a prospective, randomized, placebo-controlled study of DM patients. For weeks 0-16, patients received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies. RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications. Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-γ antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-γ) and efficacy outcome. CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-γ responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02728752.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a dermatomyozitida $x farmakoterapie $x imunologie $7 D003882
- 650 12
- $a intravenózní imunoglobuliny $x terapeutické užití $7 D016756
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a autoprotilátky $x krev $x imunologie $7 D001323
- 650 12
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Schessl, Joachim $u Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany
- 700 1_
- $a Bata-Csörgő, Zsuzsanna $u Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
- 700 1_
- $a Dimachkie, Mazen M $u Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA
- 700 1_
- $a Griger, Zoltan $u Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Moiseev, Sergey $u Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
- 700 1_
- $a Oddis, Chester V $u Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 700 1_
- $a Schiopu, Elena $u Division of Rheumatology, Medical College of Georgia at Augusta University, Augusta, GA, USA
- 700 1_
- $a Vencovský, Jiri $u Institute of Rheumatology, Research Department, and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000208510713 $7 jo20000080529
- 700 1_
- $a Clodi, Elisabeth $u Global Medical and Scientific Affairs, Octapharma Pharmazeutika Produktionsges m.b.H., Vienna, Austria
- 700 1_
- $a Levine, Todd $u Phoenix Neurological Associates, Ltd, Phoenix, AZ, USA
- 700 1_
- $a Aggarwal, Rohit $u Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA $1 https://orcid.org/0000000175318038
- 773 0_
- $w MED00011379 $t Rheumatology $x 1462-0332 $g Roč. 64, č. 6 (2025), s. 3767-3776
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39918968 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091051 $b ABA008
- 999 __
- $a ok $b bmc $g 2366419 $s 1252686
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 64 $c 6 $d 3767-3776 $e 20250601 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- GRA __
- $p Octapharma Pharmazeutika Produktionsges.m.b.H.
- GRA __
- $p Portland Medical Communications Ltd
- GRA __
- $p Octapharma
- GRA __
- $p AstraZeneca
- LZP __
- $a Pubmed-20250708
